World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
68
Citations
27867
World Ranking
7625
National Ranking
3468

Overview

Saul H. Rosenberg is affiliated with AbbVie in the United States and has contributed extensively to research intersecting biochemistry, genetics, molecular biology, and medicine. Their work spans several subfields including molecular biology, hematology, oncology, computational theory and mathematics, as well as radiology, nuclear medicine, and imaging.

The research topics that Rosenberg has focused on include:

  • Protein degradation and inhibitors
  • Ubiquitin and proteasome pathways
  • Multiple myeloma research and treatments
  • Cancer-related gene regulation
  • Computational drug discovery methods
  • Histone deacetylase inhibitors research
  • CAR-T cell therapy research

Their recent papers cover a range of high-impact topics and are published in notable scientific journals, including:

  • "Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer," 2020, Nature
  • "Target 2035 - update on the quest for a probe for every protein," 2021, RSC Medicinal Chemistry
  • "Discovery of a Potent and Selective Covalent p300/CBP Inhibitor," 2021, ACS Medicinal Chemistry Letters
  • "Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers," 2021, Molecular Cancer Therapeutics
  • "BCL-X L -targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors," 2024, Science Advances

Rosenberg frequently collaborates with several coauthors, including Chaohong Sun, Chang H. Park, Zhi-Fu Tao, Nathaniel D. Catron, and Russell A. Judge, each having coauthored at least two publications with Rosenberg.

In terms of publication venues, Rosenberg's work appears in:

  • Nature
  • RSC Medicinal Chemistry
  • ACS Medicinal Chemistry Letters
  • Science Advances
  • Molecular Cancer Therapeutics

Best Publications

  • An inhibitor of Bcl-2 family proteins induces regression of solid tumours

    Tilman Oltersdorf;Steven W. Elmore;Alexander R. Shoemaker;Robert C. Armstrong

  • ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

    Andrew J Souers;Joel D Leverson;Erwin R Boghaert;Scott L Ackler

  • ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

    Christin Tse;Alexander R. Shoemaker;Jessica Adickes;Mark G. Anderson

  • Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    Wyndham H Wilson;Owen A O'Connor;Myron S Czuczman;Ann S LaCasce

  • ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

    Cherrie K. Donawho;Yan Luo;Yanping Luo;Thomas D. Penning

  • The promise and peril of chemical probes.

    Cheryl H. Arrowsmith;James E. Audia;Christopher Austin;Jonathan Baell

  • Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

    Loren M. Lasko;Clarissa G. Jakob;Rohinton P. Edalji;Wei Qiu

  • Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation

    Le Wang;Keith W. Woods;Qun Li;Kenneth J. Barr

  • Bcl-2 family proteins are essential for platelet survival

    H Zhang;P M Nimmer;S K Tahir;J Chen

  • Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.

    Zhan Xiao;Zehan Chen;Angelo H. Gunasekera;Thomas J. Sowin

  • Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

    Joel D. Leverson;Darren C. Phillips;Michael J. Mitten;Erwin R. Boghaert

  • Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.

    Thorsten K Oost;Chaohong Sun;Robert C Armstrong;Ali-Samer Al-Assaad

  • Distinctive Roles of PHAP Proteins and Prothymosin-α in a Death Regulatory Pathway

    Xuejun Jiang;Hyun-Eui Kim;Hyun-Eui Kim;Hongjun Shu;Yingming Zhao

  • Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

    J D Leverson;H Zhang;J Chen;S K Tahir

  • Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737

    Stephen K. Tahir;Xiufen Yang;Mark G. Anderson;Susan E. Morgan-Lappe

  • Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-xL from NMR and Parallel Synthesis

    Andrew M. Petros;Jurgen Dinges;David J. Augeri;Steven A. Baumeister

  • Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

    Yan Luo;Alexander R. Shoemaker;Xuesong Liu;Keith W. Woods

  • Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

    Cheol-Min Park;Milan Bruncko;Jessica Adickes;Joy Bauch

  • Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

    Emily J. Faivre;Keith F. McDaniel;Daniel H. Albert;Srinivasa R. Mantena

  • Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth.

    Jun Chen;Wei Wu;Stephen K. Tahir;Paul E. Kroeger

Frequent Co-Authors

Hing L. Sham
Hing L. Sham Global Blood Therapeutics (United States)
Kennan C. Marsh
Kennan C. Marsh AbbVie (United States)
Eric F. Johnson
Eric F. Johnson AbbVie (United States)
Stephen W. Fesik
Stephen W. Fesik Vanderbilt University
Jun Chen
Jun Chen Nankai University
Andrew D. Hamilton
Andrew D. Hamilton New York University
Philip J. Hajduk
Philip J. Hajduk National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry in the USA opens doors to a range of rewarding online degrees and career pathways. Many students start by considering online biology degree programs, which offer flexibility and a solid foundation for further study or immediate entry into science careers.

For those interested in direct patient care, consider programs that prepare you for medical support roles. For example, online medical assistant programs fafsa approved allow you to gain clinical skills and financial aid eligibility, making them accessible and practical. If you’re already in this field, a medical assistant to lpn bridge program can help advance your qualifications and career prospects.

Nutrition is another growing niche. Aspiring nutritionists and dietitians can choose from a variety of specialized programs, including registered dietitian masters programs, which are highly valued by healthcare employers.

These diverse online pathways make it easier than ever to launch or advance your science career, wherever you are in your education or professional journey.

Best Scientists Citing Saul H. Rosenberg

Trending Scientists

Recently Published Articles